Engineered chewing gum reduced levels of HPV in the mouth by up to 93% and nearly eliminated two bacteria associated with head and neck cancer, according to a recent clinical study. The treatment preserved the broader balance of the oral microbial community, a result that the authors say could support a safer, more affordable local therapy for infection and cancer prevention.
The product is described as a specially designed gum that releases active compounds in the oral cavity during chewing, allowing sustained local exposure without systemic delivery. In the trial, participants who used the gum showed marked declines in HPV viral load and substantial reductions in two bacterial taxa previously linked to increased risk of malignancy in the upper aerodigestive tract. At the same time, commensal species commonly considered beneficial were largely retained, limiting disruption of the broader oral microbiome.
Study investigators report the dual effect — antiviral and antibacterial activity targeted to the mouth — as a notable finding because current systemic treatments can carry broader side effects and higher cost. The authors emphasize that the gum represents a targeted delivery approach that could complement vaccination and screening programs, while avoiding wholesale eradication of beneficial bacteria. They describe the results as preliminary and call for larger, controlled trials to confirm efficacy and safety over longer follow-up periods.
Next steps identified by the research team include expanded clinical testing, standardized microbiological monitoring, and assessment of long-term outcomes such as sustained viral suppression and potential impact on cancer incidence. Regulatory review and manufacturing scalability will be required before the product could be used outside trial settings. Independent evaluation and replication will be important to determine whether the approach can be integrated into public health strategies for reducing oral HPV burden and associated cancer risks.
